EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.325
-0.005 (-0.02%)
As of 3:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close21.330
Open21.410
Bid21.370 x 1800
Ask21.380 x 4000
Day's Range21.140 - 21.620
52 Week Range18.500 - 32.500
Volume2,093,908
Avg. Volume4,572,853
Market Cap6.331B
Beta2.34
PE Ratio (TTM)26.36
EPS (TTM)0.809
Earnings DateAug 1, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.17
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018

    Exelixis, Inc. (EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

  • See what the IHS Markit Score report has to say about Exelixis Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $22 million.

  • Investopedia8 days ago

    Top 5 Biotech Stocks for 2018

    Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.

  • Why Analysts are Mostly Positive On Acceleron Pharma
    Market Realist10 days ago

    Why Analysts are Mostly Positive On Acceleron Pharma

    After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.

  • See what the IHS Markit Score report has to say about Exelixis Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 5. Index (PMI) data, output in the Healthcare sector is rising.

  • Analysts Are Mostly Positive on Exelixis in July
    Market Realist14 days ago

    Analysts Are Mostly Positive on Exelixis in July

    On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10. On June 26, Exelixis stock rose ~8.0% to close at $21.03 from its previous day’s close of $19.54 on June 25. 

  • Business Wire15 days ago

    Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine

    – Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma –

  • Understanding Exelixis’s Valuations and Cash Flow Trend
    Market Realist16 days ago

    Understanding Exelixis’s Valuations and Cash Flow Trend

    In the first quarter of 2018, Exelixis (EXEL) generated $71.8 million from operating activities compared to $68.85 million in Q1 2017. The increase in operating cash flow was primarily attributable to the increase in Exelixis’s net income, offset by an increase in trade and other receivables of $10.75 million in Q1 2018 compared to a decrease of $6.54 million in Q1 2017. It was also attributable to unbilled collaboration revenue of $38 million in Q1 2018 and a decrease in deferred revenues of $2.65 million compared to an increase of $35.14 million in Q1 2017.

  • Taking Stock of Exelixis’s Operational Performance
    Market Realist16 days ago

    Taking Stock of Exelixis’s Operational Performance

    Exelixis (EXEL) has collaboration agreements with Ipsen, Takeda, and Genentech. Revenues from Ipsen increased from $4.5 million in Q1 2017 to $53.81 million in Q1 2018. Under Exelixis’s collaboration with Takeda for cabozantinib, revenues were $2.92 million in Q1 2018 compared to $2.68 million in Q1 2017. Revenues from Genentech on the US commercialization of Cotellic were $1.34 million in Q1 2018 compared to $2.29 million in Q1 2017.

  • Analyzing Exelixis’s Revenue Trend
    Market Realist16 days ago

    Analyzing Exelixis’s Revenue Trend

    Exelixis (EXEL) generated total revenues of $212.34 million in Q1 2018 compared to $80.88 million in Q1 2017. It generates revenues from product sales and collaborations. Exelixis’s collaboration revenues also registered strong growth in the quarter, rising from $12 million in Q1 2017 to $78 million in Q1 2018.

  • How Much Upside Do Analysts See in Exelixis Stock?
    Market Realist16 days ago

    How Much Upside Do Analysts See in Exelixis Stock?

    Exelixis (EXEL) is a biotechnology company focused on discovering, developing, and commercializing drugs to treat cancer. Two of them—Cabometyx and Cometriq—are derived from cabozantinib, a multiple tyrosine kinase inhibitor. Exelixis’s third commercial product, Cotellic, is a MEK inhibitor approved as part of a combination therapy for advanced melanoma and is marketed in collaboration with Genentech.

  • See what the IHS Markit Score report has to say about Exelixis Inc.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    Exelixis Inc NASDAQ/NGS:EXEL

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool21 days ago

    3 Top Healthcare Stocks to Buy Right Now

    A cancer-drug developer, generic-drug manufacturer, and medical device kingpin may be just what the doctor ordered.

  • Exelixis (EXEL) Jumps: Stock Rises 8%
    Zacks22 days ago

    Exelixis (EXEL) Jumps: Stock Rises 8%

    Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Business Wire22 days ago

    Exelixis to Be Added to the S&P MidCap 400 Index

    Exelixis, Inc. (EXEL) today announced that it will be added to Standard & Poor’s (S&P) MidCap 400 index, effective prior to the open of trading on Monday, July 2. The company will be classified under S&P’s Global Industry Classification Standard (GICS) Biotechnology Sub-Industry index. “S&P is a highly respected organization in the investment and financial communities, so Exelixis’ addition to the S&P MidCap 400 is an important milestone as we continue on our growth trajectory,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis.

  • Benzinga23 days ago

    Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 25) Quest Diagnostics Inc (NYSE: DGX )(Barclays upgraded shares ...

  • Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
    Motley Fool23 days ago

    Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

    Which of these cancer-focused biotech stocks is the better pick right now?

  • ACCESSWIRE23 days ago

    Today's Research Reports on Trending Tickers: Exelixis and Zafgen

    NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...

  • PR Newswire24 days ago

    Copart Set to Join S&P 500; Exelixis to Join S&P MidCap 400; Clarifications to S&P U.S. Indices Methodology

    NEW YORK, June 25, 2018 /PRNewswire/ -- S&P MidCap 400 constituent Copart Inc. (CPRT) will replace Dr Pepper Snapple Group Inc. (DPS) in the S&P 500, and Exelixis Inc. (EXEL) will replace Copart in the S&P MidCap 400 effective prior to the open of trading on Monday, July 2. Dr Pepper Snapple Group, which is merging with privately held Keurig Green Mountain Inc., is changing its name to Keurig Dr Pepper Inc. and its ticker symbol (NYSE:KDP) in a transaction expected to be completed soon. The newly combined company will no longer be eligible for inclusion in the S&P 500 as its Investable Weight Factor (IWF), which measures the percentage of free float available to the public, is expected to fall well below the 50% eligibility threshold needed for continued inclusion in the index.

  • ACCESSWIRE28 days ago

    Today's Research Reports on Trending Tickers: bluebird bio and Exelixis

    NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...

  • Exelixis Inc (NASDAQ:EXEL) Has Attractive Fundamentals, Here’s Why
    Simply Wall St.28 days ago

    Exelixis Inc (NASDAQ:EXEL) Has Attractive Fundamentals, Here’s Why

    Attractive stocks have exceptional fundamentals. In the case of Exelixis Inc (NASDAQ:EXEL), there’s is a financially-healthy company with a great history and an optimistic growth outlook. Below is a briefRead More...

  • ACCESSWIRE28 days ago

    Stock Performance Review on Exelixis and Three Other Biotech Stocks

    Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Endocyte Inc. (NASDAQ:ECYT), Epizyme Inc. (EPZM), Esperion Therapeutics Inc. (ESPR), and Exelixis Inc. (EXEL).All you have to do is sign up today for this free limited time offer by clicking the link below. West Lafayette, Indiana headquartered Endocyte Inc.'s stock finished Wednesday's session 3.46% higher at $14.64.

  • CNBClast month

    Cramer's lightning round: GE's CEO was dealt 'one of the worst hands that anyone’s ever been given'

    It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. General Electric Company GE : "[CEO] John Flannery is doing his best with one of the worst hands that anyone's ever been given. The company just was not forthcoming.' Now that they're being forthcoming, all I can say is listen to [J.P. Morgan JPM analyst] Steve Tusa.

  • Why I Like Exelixis Inc (NASDAQ:EXEL)
    Simply Wall St.last month

    Why I Like Exelixis Inc (NASDAQ:EXEL)

    As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...

  • GlobeNewswirelast month

    Consolidated Research: 2018 Summary Expectations for Rayonier Advanced Materials, CYS Investments, Avid Bioservices, American Airlines Group, Exelixis, and International Business Machines — Fundamental Analysis, Key Performance Indications

    NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rayonier ...